Evidence based application of BNP/NT-proBNP testing in heart failure

Clinical Biochemistry

Volumn 48, Issue 4-5, 2015, Pages 236-246

  Don Wauchope, Andrew C ^a   McKelvie, Robert S ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

B type natriuretic peptides; BNP; Heart failure; NT proBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; BODY MASS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; HEART FAILURE; HUMAN; KIDNEY FUNCTION; META ANALYSIS; PEPTIDE ANALYSIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; ANIMAL; BLOOD; EVIDENCE BASED MEDICINE; PROCEDURES; STANDARDS;

ANIMALS; BIOMARKERS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84924616488     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.11.002     Document Type: Review

References (69)

1. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J.V., Ponikowski P., Poole-Wilson P.A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 933-989.
2. Arnold J.M.O., Liu P., Demers C., Dorian P., Giannetti N., Haddad H., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 23-45.
3. Davie A.P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use?. QJM 1997, 90:335-339.
4. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009, 13:1-207. 10.3310/hta13320.
5. Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., van Velzen E., Wielders J.P., et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011, 13:518-527. 10.1093/eurjhf/hfr021.
6. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006, 11:95-107. 10.1007/s10741-006-9481-0.
7. Kelder J.C., Cramer M.J., van W.J., van T.R., Mosterd A., Moons K.G., et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circ Heart Fail 2011, 124:2865-2873.
8. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, e154-e235.
9. McDonagh T.A., Morrison C.E., Lawrence A., Ford I., Tunstall-Pedoe H., McMurray J.J., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997, 350:829-833. 10.1016/S0140-6736(97)03033-X.
10. Morgan S., Smith H., Simpson I., Liddiard G.S., Raphael H., Pickering R.M., et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ (Clinical research Ed.) 1999, 318:368-372.
11. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245. 10.1161/CIR.0b013e31828124ad.
12. Rich M.W. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A: Biol Med Sci 2001, 56:M88-M96.
13. Bleumink G.S., Knetsch A.M., Sturkenboom M.C.J.M., Straus S.M.J.M., Hofman A., Deckers J.W., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004, 25:1614-1619. 10.1016/j.ehj.2004.06.038.
14. Lee D.S., Johansen H., Gong Y., Hall R.E., Tu J.V., Cox J.L., et al. Regional outcomes of heart failure in Canada. CJCA 2004, 20:599-607.
15. Omland T., Hagve T.-A. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009, 5:471-487. 10.1016/j.hfc.2009.04.005.
16. Liquori M.E., Christenson R.H., Collinson P.O., deFilippi C.R. Cardiac biomarkers in heart failure. Clin Biochem 2014, 47:327-337. 10.1016/j.clinbiochem.2014.01.032.
17. Chenevier-Gobeaux C., Guerin S., Andre S., Ray P., Cynober L., Gestin S., et al. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: A comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 2010, 56:1708-1717.
18. Hu Z., Han Z., Huang Y., Sun Y., Li B., Deng A. Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea: a meta-analysis. Clin Biochem 2012, 45:1634-1639. 10.1016/j.clinbiochem.2012.08.028.
19. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration 2009, J.P. Higgins, S. Green (Eds.).
20. DiCenso A., Bayley L., Haynes R.B. ACP Journal Club. Editorial: Accessing preappraised evidence: fine-tuning the 5S model into a 6S model. Ann Intern Med 2009, 151. [JC3-2 - JC3]. 10.7326/0003-4819-151-6-200909150-02002.
21. Krum H., Jelinek M.V., Stewart S., Sindone A., Atherton J.J. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011, 194:405-409.
22. McMurray J.J.V., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 803-869.
23. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 10.1161/CIR.0b013e31829e8776.
24. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926. 10.1136/bmj.39489.470347.AD.
25. McKelvie R.S., Moe G.W., Ezekowitz J.A., Heckman G.A., Costigan J., Ducharme A., et al. The 2012 Canadian cardiovascular society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013, 29:168-181. 10.1016/j.cjca.2012.10.007.
26. Clinical practice guidelines we can trust 2011, 1-2. The National Academies Press. R. Graham, M. Mancher, M.D. Wolman, S.M. Greenfield (Eds.).
27. Glasziou P., Vandenbroucke J.P., Chalmers I. Assessing the quality of research. BMJ 2004, 328:39-41. 10.1136/bmj.328.7430.39.
28. Chang S.M., Matchar D.B. Methods guide for medical test reviews 2012, 1-188. Agency for Healthcare Research and Quality (US).
29. Balion C., Don-Wauchope A., Hill S., Santaguida P.L., Booth R., Brown J.A., et al. Use of natriuretic peptide measurement in the management of heart failure 2013, Agency for Healthcare Research and Quality (US), Rockville (MD).
30. Worster A., Balion C.M., Hill S.A., Santaguida P., Ismaila A., McKelvie R., et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. Clin Biochem 2008, 41:250-259. 10.1016/j.clinbiochem.2007.08.008.
31. Santaguida P.L., Don-Wauchope A.C., Oremus M., McKelvie R., Ali U., Hill S.A., et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 2014, 19:453-470. 10.1007/s10741-014-9442-y.
32. Santaguida P.L., Don-Wauchope A.C., Ali U., Oremus M., Brown J.A., Bustamam A., et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev 2014, 19:507-519. 10.1007/s10741-014-9444-9.
33. Oremus M., Don-Wauchope A., McKelvie R., Santaguida P.L., Hill S., Balion C., et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev 2014, 19:471-505. 10.1007/s10741-014-9439-6.
34. Hill S.A., Booth R.A., Santaguida P.L., Don-Wauchope A., Brown J.A., Oremus M., et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev 2014, 19:421-438. 10.1007/s10741-014-9447-6.
35. Don-Wauchope A.C., Santaguida P.L., Oremus M., McKelvie R., Ali U., Brown J.A., et al. Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review. Heart Fail Rev 2014, 19:521-540. 10.1007/s10741-014-9443-x.
36. Booth R.A., Hill S.A., Don-Wauchope A., Santaguida P.L., Oremus M., McKelvie R., et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev 2014, 19:439-451. 10.1007/s10741-014-9445-8.
37. Balion C.M., McKelvie R.S., Reichert S., Santaguida P., Booker L., Worster A., et al. Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: Is BNP or NT-proBNP a useful assessment tool?. Clin Biochem 2008, 41:266-276. 10.1016/j.clinbiochem.2007.10.006.
38. Balion C., Santaguida P.L., Hill S., Worster A., McQueen M., Oremus M., et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure: evidence report/technology assessment, No. 142. AHRQ publication No. 06-E014 2006, Agency for Healthcare Research and Quality (US), Rockville (MD).
39. Balion C., McKelvie R., Don-Wauchope A.C., Santaguida P.L., Oremus M., Keshavarz H., et al. B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev 2014, 19:553-564. 10.1007/s10741-014-9451-x.
40. Battaglia M., Pewsner D., Jüni P., Egger M., Bucher H.C., Bachmann L.M. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 2006, 166:1073-1080. 10.1001/archinte.166.10.1073.
41. Doust J.A., Glasziou P.P., Pietrzak E., Dobson A.J. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004, 164:1978-1984. 10.1001/archinte.164.18.1978.
42. Ewald B., Ewald D., Thakkinstian A., Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008, 38:101-113. 10.1111/j.1445-5994.2007.01454.x.
43. Clerico A., Fontana M., Zyw L., Passino C., Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007, 53:813-822. 10.1373/clinchem.2006.075713.
44. Latour-Pérez J., Coves-Orts F.J., Abad-Terrado C., Abraira V., Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail 2006, 8:390-399. 10.1016/j.ejheart.2005.10.004.
45. Guyatt G.H., Oxman A.D., Kunz R., Woodcock J., Brozek J., Helfand M., et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011, 64:1294-1302. 10.1016/j.jclinepi.2011.03.017.
46. Ferrandis M.-J., Ryden I., Lindahl T.L., Larsson A. Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med Sci 2013, 118:75-79. 10.3109/03009734.2012.751471.
47. Campbell S.M., Fuat A., Summerton N., Lancaster N., Hobbs F.R. Diagnostic triage and the role of natriuretic peptide testing and echocardiography for suspected heart failure: an appropriateness ratings evaluation by UK GPs. Br J Gen Pract 2011, 61:e427-e435. 10.3399/bjgp11X583218.
48. Doust J.A., Pietrzak E., Dobson A., Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ (Clinical research Ed.) 2005, 330:625-627. 10.1136/bmj.330.7492.625.
49. Di Angelantonio E., Chowdhury R., Sarwar N., Ray K.K., Gobin R., Saleheen D., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187. 10.1161/CIRCULATIONAHA.109.884866.
50. Don-Wauchope A.C., Santaguida P.L., McKelvie R., Brown J.A., Oremus M., Ali U., et al. Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review. Heart Fail Rev 2014, 19:541-551. 10.1007/s10741-014-9446-7.
51. Vesbianu D., Vesbianu C., Bernstein P., Kouides R. Plasma brain natriuretic peptide - An independent predictor of mortality and rehospitalization in congestive heart failure - A meta-analysis. World Heart J 2008, 1:349-354.
52. Alba A.C., Agoritsas T., Jankowski M., Courvoisier D., Walter S.D., Guyatt G.H., et al. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail 2013, 6:881-889. 10.1161/CIRCHEARTFAILURE.112.000043.
53. D'Agostino R., Byung-Ho N. Evaluation of the performance of survival analysis models: discrimination and calibration measures. Handbook of statistics v23: advances in survival analysis 2004, 1-26. Elsevier, Amsterdam, The Netherlands. N. Balakrishnan, C. Rao (Eds.).
54. Nunez J., Nunez E., Robles R., Bodi V., Sanchis J., Carratala A., et al. Prognostic value of brain natriuretic peptide in acute heart failure: Mortality and hospital readmission. Rev Esp Cardiol 2008, 61:1332-1337.
55. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., Casas T., Garrido I.P., Bonaque J.C., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725. 10.1093/eurjhf/hfr047.
56. Zairis M.N., Tsiaousis G.Z., Georgilas A.T., Makrygiannis S.S., Adamopoulou E.N., Handanis S.M., et al. Multimarker strategy for the prediction of 31days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 2010, 141:284-290.
57. Heidenreich P.A., Albert N.M., Allen L.A., Bluemke D.A., Butler J., Fonarow G.C., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013, 6:606-619. 10.1161/HHF.0b013e318291329a.
58. Calvin J.E., Shanbhag S., Avery E., Kane J., Richardson D., Powell L. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail 2012, 18:73-78. 10.1111/j.1751-7133.2011.00263.x.
59. Komajda M., Lapuerta P., Hermans N., Gonzalez-Juanatey J.R., van Veldhuisen D.J., Erdmann E., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005, 26:1653-1659. 10.1093/eurheartj/ehi251.
60. Yancy C.W., Fonarow G.C., Albert N.M., Curtis A.B., Stough W.G., Gheorghiade M., et al. Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol 2010, 105:255-260. 10.1016/j.amjcard.2009.08.681.
61. Troughton R.W., Richards A.M., Yandle T.G., Frampton C.M., Nicholls M.G. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med 2007, 39:242-260. 10.1080/07853890701232057.
62. De Vecchis R., Esposito C., Di Biase G., Ariano C., Giasi A., Cioppa C. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. J Cardiovasc Med (Hagerstown, Md) 2014, 15:122-134. 10.2459/JCM.0b013e328364bde1.
63. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430. 10.1016/j.ahj.2009.06.018.
64. Li P., Luo Y., Chen Y.-M. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ 2013, 22:852-860. 10.1016/j.hlc.2013.03.077.
65. Porapakkham P., Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med 2010, 170:507-514. 10.1001/archinternmed.2010.35.
66. Savarese G., Trimarco B., Dellegrottaglie S., Prastaro M., Gambardella F., Rengo G., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 2013, 8:e58287. 10.1371/journal.pone.0058287.
67. Troughton R.W., Frampton C.M., Brunner-La Rocca H.-P., Pfisterer M., Eurlings L.W.M., Erntell H., et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014, 35:1559-1567. 10.1093/eurheartj/ehu090.
68. Xin W., Lin Z., Mi S. Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 2014, 10.1007/s10741-014-9437-8.
69. Gaggin H.K., Mohammed A.A., Bhardwaj A., Rehman S.U., Gregory S.A., Weiner R.B., et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 2012, 18:626-634. 10.1016/j.cardfail.2012.05.005.